RTSM

In an adaptive oncology trial, the RTSM must do four things that a conventional randomization system is not required to do: enforce configurable cohort and dose assignment rules in real [...]

Biomarker-driven oncology trials enroll slowly because eligibility depends on a chain of steps — tissue procurement, sample shipment, lab processing, result communication, and site decision — each owned by a [...]

Adaptive oncology trials fail operationally, not statistically. Learn what data readiness, RTSM configuration, and DSMB preparation actually require in execution.

Drug supply management in an umbrella trial requires RTSM configuration that explicitly models arm expansion and arm closure scenarios — not supply planning for the initial design with manual adjustments [...]

Data readiness for adaptive trial interim analysis is an operational problem solved months before the window arrives. Here's what must be true before your DSMB can decide.

Explore how Sitero’s RTSM platform enabled a top 5 pharma company to streamline their randomization and supply management across complex global studies in our latest case study: